Sudhir Agrawal, D. Phil., FRSC, is the founder and president of ARNAY Sciences. He also serves as an Affiliate Professor in the Department of Medicine at UMass Chan Medical School. For over thirty years, his research has concentrated on developing RNA therapeutics. He has specialized in the chemistry and chemical engineering of oligonucleotides to enhance the drug-like properties of RNA therapies. He has authored over 300 research papers, chapters, reviews, and more than 450 patents and applications worldwide. Additionally, he has edited four books on oligonucleotides and antisense technology, including “Advances in Nucleic Acid Therapeutics,” which he co-edited with Mike Gait and published with The Royal Society of Chemistry. He currently sits on the scientific advisory boards of several biotechnology companies.

He earned his D.Phil. in Chemistry from Allahabad University in India and conducted postdoctoral research with Mike Gait at the MRC Laboratory of Molecular Biology in Cambridge, UK. His research in the antisense field began in the late eighties in Paul Zamecnik’s laboratory at the Worcester Foundation for Experimental Biology, Shrewsbury, MA, USA, now UMass Chan Medical School. He is a co-founder of Idera Pharmaceuticals and held various roles until 2017.

In 2022, the Oligonucleotide Therapeutics Society awarded him the Lifetime Achievement Award.